The PCR-based DNA fingerprinting method called the methylation-sensitive amplified fragment length polymorphism (MS-AFLP) analysis is used for genome-wide scanning of methylation status. In this study, we developed a method of fluorescence-labeled MS-AFLP (FL-MS-AFLP) analysis by applying a fluorescence-labeled primer and fluorescence-detecting electrophoresis apparatus to the existing method of MS-AFLP analysis. The FL-MS-AFLP analysis enables quantitative evaluation of more than 350 random CpG loci per run. It was shown to allow evaluation of the differences in methylation level of blood DNA of gastric cancer patients and evaluation of hypermethylation and hypomethylation in DNA from gastric cancer tissue in comparison with adjacent non-cancerous tissue.
INTRODUCTION
Transcription silencing by CpG island promoter hypermethylation has been linked to tumor suppressor gene inactivation (1) (2) (3) , and DNA hypomethylation has been shown to play a role in cancer gene expression (4, 5) . Thus, to better understand the abnormal gene expression in human cancer, it is important to develop an effective system for detection of hypermethylation and hypomethylation in DNA. Since a recently developed PCR-based DNA fingerprinting method called methylation-sensitive amplified fragment length polymorphism (MS-AFLP) analysis enables simultaneous genome-wide detection of DNA hypermethylation and hypomethylation in tumor tissue in comparison with adjacent normal tissue, it is one of the most useful approaches to cancer research related to DNA hypermethylation and hypomethylation (6, 7) . However, since MS-AFLP analysis is a radioisotope-based method, determinations of hypermethylation and hypomethylation are made by visual inspection of X-ray film, meaning there is subjective aspect to the determinations. Moreover, only about 150 CpG loci in one sample can be analysed per run (6, 7) . We therefore improved the original method of MS-AFLP analysis in order to enable evaluation of larger numbers of CpG loci in a quantitative fashion.
MATERIALS AND METHODS

MATERIALS
Lung cancer cell line A549 was purchased from the American Type Culture Collection (ATCC). Blood samples were obtained from patients who had undergone surgery for gastric cancer at Iwata City Hospital. Gastric cancer tissue and adjacent non-cancerous tissue were obtained from the surgical specimens of patients who had undergone surgery For reprints and all correspondence: Haruhiko Sugimura, 1st Department of Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka 431-3192, Japan. E-mail: hsugimur@ hama-med.ac.jp for gastric cancer at Hamamatsu University School of Medicine, University Hospital. The study was approved by the Institutional Review Board (IRB) of Iwata City Hospital and the IRB of Hamamatsu University School of Medicine.
5-AZA-2'-DEOXYCYTIDINE TREATMENT A549 cells were treated for 48 h with freshly prepared 5-aza-2'-deoxycytidine (Aza-dC) at a final concentration of 2 mM, as described previously (8) .
MICRODISSECTION
Frozen sections of the gastric cancers were stained with hematoxylin and eosin (HE). Cancerous cell clusters in stained sections were examined and microdissected under an inverted microscope (Olympus IX71; Olympus, Tokyo, Japan) equipped with a microdissection device (MicroDissector; Eppendorf AG, Hamburg, Germany). Areas of interest were microdissected with an ultrasonically oscillating needle, and the tissue particles obtained were aspirated into a pipette tip with a piezo-driven micropipette.
FLUORESCENCE-LABELED MS-AFLP (FL-MS-AFLP)
Genomic DNA was extracted with a DNeasy Kit (QIAGEN, Valencia, CA, USA) (9) . A 500 ng sample of genomic DNA was digested overnight at 378C with 5 U of the methylation-sensitive restriction enzyme NotI (New England Biolabs, Beverly, MA, USA) and 2 U of the methylation-insensitive restriction enzyme MseI (New England Biolabs) (Fig. 1a) . Two pairs of oligonucleotides were annealed overnight at 378C to generate a NotI-specific adaptor (5'-GAC GAT GAG TCC TGA G-3' and 5'-TAC TCA GGA CTC AT-3') and an MseI-specific adaptor (5'-CTC GTA GAC TGC GTA GG-3' and 5'-GGC CCC TAC GCA GTC TAC-3'). The digested DNA was ligated overnight at 168C to the NotI adaptor and the MseI adaptor with 1 U of T4 DNA ligase (Promega, Madison, WI, USA) (Fig. 1b) . The adaptor-ligated template DNA was amplified by PCR with AmpliTaq DNA polymerase (Applied Biosystems, Tokyo, Japan) and a set of primers consisting of fluorescein isothiocyanate (FITC)-labeled NotI primer (5'-FITC-GAC TGC GTA GGG GCC GCG-3') and nonlabeled MseI primer (5'-GAT GAG TCC TGA GTA AC-3') ( Fig. 1c) . The PCR was started at 728C for 30 s, then 948C for 30 s, and followed by 36 cycles of 948C for 30 s, 528C for 30 s and 728C for 2 min. The final extension was performed for 10 min at 728C. After heat denaturing, the fluorescent PCR products were separated and analysed on an automatic DNA sequencer (DSQ-2000, Shimadzu Co., Kyoto, Japan). FITC-conjugated 400 bp marker and 1 kb marker (Bio Ventures, Murfreesboro, TN, USA) were used as DNA size standards.
RESULTS
We developed a method of FL-MS-AFLP analysis by applying an FITC-labeled NotI primer and fluorescence-detecting electrophoresis apparatus (DSQ-2000) to the existing method of MS-AFLP analysis (6, 7) . In the new method, the FITC-labeled NotI primer is used in the PCR amplification after restriction enzyme digestion and adaptor ligation instead of the non-labeled primer with 32 P radioisotope ( Fig. 1a -c) , and the FITC contained in the PCR product is analysed on a DSQ-2000 automatic DNA sequencer. To assess the effectiveness of the FL-MS-AFLP analysis, we first used it to analyse the genomic DNA of A549 cells treated with Aza-dC. Fluorescence-labeled methylation-sensitive amplified fragment length polymorphism analysis
Since Aza-dC is a demethylating agent, an increase in unmethylated NotI sites, i.e. increase in FITC-labeled PCR products, was expected. As shown in Fig. 1d , multiple CpG loci amplified by PCR were detected by the electropherogram as well as the electrophoretic ladder (fingerprint), and we were able to use the electropherogram to quantitatively evaluate alterations in the signal intensity of each CpG loci. As expected, many more CpG loci of signal intensity increase, i.e. hypomethylation, were detected in the sample treated with Aza-dC in comparison with the sample not treated with 
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Fluorescence-labeled methylation-sensitive amplified fragment length polymorphism analysis Aza-dC. Moreover, we were able to evaluate a total of more than 350 CpG loci between 60 bp long and 1000 bp long, a larger number than can be evaluated by MS-AFLP analysis (6, 7) . All of the results were highly reproducible. Next, we attempted to determine whether FL-MS-AFLP analysis can be used to evaluate differences between the methylation status of blood DNA from gastric cancer patients. When the methylation status of blood DNA from a gastric cancer patient was compared with that of blood DNA from all the other gastric cancer patients (Fig. 2) , different bands of signal intensity increase (hypomethylation) and signal intensity decrease (hypermethylation) were detected, suggesting that FL-MS-AFLP analysis enables evaluation of differences in the methylation level of the blood DNA among gastric cancer patients.
Next, we attempted to determine whether FL-MS-AFLP analysis can be used to evaluate hypermethylation and hypomethylation in the DNA from gastric cancer tissue in comparison with adjacent non-cancerous tissue. As shown in Fig. 3 , various bands of cancer-specific hypomethylation and hypermethylation were detected, suggesting that FL-MS-AFLP analysis makes it possible to evaluate the alterations in the methylation level of DNA from gastric cancer in comparison with adjacent non-cancerous tissue.
DISCUSSION
In this study, we succeeded in developing a method of FL-MS-AFLP analysis by applying a fluorescence-labeled primer and fluorescence-detecting electrophoresis apparatus to the existing MS-AFLP analysis method. The results showed that it was possible to quantitatively evaluate more than 350 random CpG loci per run by FL-MS-AFLP analysis. They also showed that this new method makes it possible to evaluate differences in the methylation level of the blood DNA of gastric cancer patients and to evaluate hypermethylation and hypomethylation in the DNA from gastric cancer tissue in comparison with adjacent non-cancerous tissue.
More than 350 random CpG loci per lane per run were quantitatively evaluated by FL-MS-AFLP analysis, and thus, its capacity to detect PCR-amplified bands corresponding to CpG loci is more than two-fold that of MS-AFLP analysis (6, 7) . The increase in number is attributable to the difference in gel size and electrophoresis apparatus. The glass plate is longer (61 versus 37 cm), and a fluorescence-detecting automatic DNA sequencer is used for FL-MS-AFLP analysis, whereas, a conventional sequencing gel electrophoresis apparatus designed for sequence determination of up to 250 -350 bases is used for MS-AFLP analysis. The result is an increase in resolution and range of bands discernible by FL-MS-AFLP analysis, and in actual practice, a fragment as long as 1000 bases can be analysed. In addition, FL-MS-AFLP analysis allows determination of the presence or absence of alterations in signal intensity by comparing signal heights on the electropherogram. This means that FL-MS-AFLP analysis is a more quantitative method than MS-AFLP analysis, which requires alterations in the band signal intensity to be evaluated by visual inspection of X-ray film. With regard to sensitivity, since signals more than 1.4-fold higher than noise can be detected as a band by FL-MS-AFLP analysis, whereas signals more than approximately two-fold higher than noise can be detected as a band by MS-AFLP analysis, FL-MS-AFLP analysis is slightly more sensitive than MS-AFLP analysis. However, since the signals of the majority (95%) of the bands detected by FL-MS-AFLP analysis were more than 10-fold higher than noise, the difference in sensitivity makes only a small contribution to the increase in the bands detected. There are two other advantages to the use of the fluorescent tag. One is that FL-MS-AFLP analysis is safer and can be performed in the facilities that do not have a radioisotope center. The other is that the fluorescence-labeled primers have a long life in comparison with the short half-life of 32 P (14.3 days). Thus, experiments can be performed more economically by FL-MS-AFLP analysis instead of radioactive MS-AFLP analysis. All of the above indicate that FL-MS-AFLP analysis is superior to MS-AFLP analysis.
Although an experimental trial of the use of fluorescence for MS-AFLP analysis of one tumor was briefly noted by Yamamoto et al. (6) , only about 60 peak signals could be detected, perhaps because of the difference between their experimental system and ours. The advantages of our study compared with theirs are (i) a marked increase (more than five times) in the number of CpG loci evaluated, (ii) demonstration of the use of three different kinds of materials, (iii) a detailed explanation of method and results of FL-MS-AFLP analysis and (iv) demonstration that FL-MS-AFLP analysis can be used to evaluate differences in the methylation level of DNA in blood.
Recent studies have shown that subsets of genes are hypermethylated or hypomethylated in peripheral blood DNA, and these alterations are speculated to be associated with carcinogenesis. However, the studies have been performed only on certain genes, such as p53, CDH1, p16, MGMT and DAPK (10 -12). The present study (Fig. 2) showed that multiple CpG loci in blood DNA can be evaluated quantitatively and simultaneously by FL-MS-AFLP analysis. If FL-MS-AFLP analysis is used to evaluate blood DNA in a large-scale cancer case-control series, methylated or demethylated genes associated with cancer risk may be found. In the past several years, rapid progress has been made in research on cancer-tissue-specific DNA hypermethylation and hypomethylation (1 -5,13), however, not all of the hypermethylated or hypomethylated genes in cancer have been found. FL-MS-AFLP analysis may lead to the discovering of novel cancer-specific hypermethylated or hypomethylated genes.
